TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03733158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The new Flexible Tip Bougie catheter
Description: intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The new Flexible Tip Bougie catheter
Description: intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The new Flexible Tip Bougie catheter
Description: intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter
Study: NCT02651610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Biological: bavituximab
Study: NCT03733158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The new Flexible Tip Bougie catheter
Description: intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter
Study: NCT03311594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Alcohol
Description: Low Alcohol Consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Alcohol
Description: Low Alcohol Consumption
Study: NCT01163747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
Study: NCT02651610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane
Description: Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
Study: NCT03311594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Alcohol
Description: Moderate Alcohol Consumption
Study: NCT01163747

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine
Description: Intramuscular or subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-Valent Pneumococcal Polysaccharide Vaccine
Description: Intramuscular or subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid Adsorbed Vaccine
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid Adsorbed Vaccine
Description: Intramuscular injection
Study: NCT02250495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sympara Therapeutic System
Description: Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
Study: NCT03311594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate Alcohol
Description: Moderate Alcohol Consumption

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alcohol
Description: Placebo Alcohol Consumption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Alcohol
Description: Placebo Alcohol Consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Induction
Description: 10% capsaicin solution placed on forearm and heat induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Induction
Description: 10% capsaicin solution placed on forearm and heat induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Induction
Description: 10% capsaicin solution placed on forearm and heat induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Induction
Description: 10% capsaicin solution placed on forearm and heat induction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Pain Induction
Description: Water placed on forearm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Pain Induction
Description: Water placed on forearm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Pain Induction
Description: Water placed on forearm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Pain Induction
Description: Water placed on forearm
Study: NCT00378547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol + placebo + placebo
Description: Comparing the analgesic effect of combinations of paracetamol + placebo + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol + pregabalin + placebo
Description: Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol + pregabalin + dexamethasone
Description: Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
Study: NCT04147845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fractional Carbon Dioxide Laser
Description: The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fractional Carbon Dioxide Laser
Description: The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microneedling using dermapen
Description: Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microneedling using dermapen
Description: Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: The applied PRP will be spread over the whole affected area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: The applied PRP will be spread over the whole affected area
Study: NCT02510118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
Study: NCT02651610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
Study: NCT00564928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
Study: NCT01882725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia HP Scanner (HPS)
Description: The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
Study: NCT00986960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repository corticotropin injection
Description: IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
Study: NCT04102150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat Tosylate
Description: Once a day, 200 mg, oral administration
Study: NCT02865369

Intervention type: DRUG
Intervention: Daclatasvir and Asunaprevir
Description: Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
Study: NCT01854177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02515695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
Study: NCT04331301

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Vapo-Enucleation of the prostate
Description: group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Needlescopic Enucleation of the prostate
Description: group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
Study: NCT02654925

Intervention type: PROCEDURE
Intervention: Adipose Tissue Biopsy

Intervention type: PROCEDURE
Intervention: Adipose Tissue Biopsy

Intervention type: PROCEDURE
Intervention: Adipose Tissue Biopsy
Study: NCT00458536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Fusion Vaccine
Description: 3 vaccinations at three week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Fusion Vaccine
Description: 3 vaccinations at three week intervals
Study: NCT02510118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ChangTai Keli
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChangTai Keli
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
Study: NCT02430272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
Study: NCT02762422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Removal of 500 cc of blood via forearm vein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Removal of 500 cc of blood via forearm vein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phlebotomy
Description: Removal of 500 cc of blood via forearm vein
Study: NCT02139826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01
Study: NCT03153540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active iTBS
Description: Intermittent theta burst transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Sham intervention
Study: NCT02458625

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose 500 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose 500 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron bisglycinate 60 mg
Study: NCT00000261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Nitrous oxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No drug (100% oxygen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4% sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% sevoflurane
Study: NCT00458536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Description: Combined with the vaccine in the remaining subjects after the first 6 are enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Description: Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
Study: NCT00285207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 days of 28 day cycle for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A007
Description: 5 days of 28 day cycle
Study: NCT02422940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine-ER 7.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine-ER 10 mg
Study: NCT02782949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01094561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic Human Secretin
Description: Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secretin-Enhanced Magnetic Resonance Cholangiopancreatography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secretin-Enhanced Endoscopic Ultrasound
Study: NCT02104739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)
Study: NCT04069221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of 800 mg OZ439
Description: Single oral dose of 800 mg OZ439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of 800 mg OZ439
Description: Single oral dose of 800 mg OZ439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg OZ439
Description: Single oral dose of 400 mg OZ439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg OZ439
Description: Single oral dose of 400 mg OZ439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single oral dose of cobicistat
Description: Single oral dose of 150 mg cobicistat
Study: NCT02654925

Intervention type: PROCEDURE
Intervention: Adipose Tissue Biopsy
Study: NCT01412437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diet
Description: 12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Description: 20 mg/kg for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Study: NCT03359603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments.
Study: NCT01451333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg qd; 3 x 200mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 400mg qd; 2 x 200mg
Study: NCT02560454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed
Description: Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presco
Description: Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances.